Pharmaceutical

Amylyx ventures into metabolic diseases market with $35.1m deal

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Jun 30, 2024 - 04:00
Amylyx ventures into metabolic diseases market with $35.1m deal
On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.
Read the original article

Tags:

Previous Article

Supreme Court votes against Purdue Pharma’s opioid settlement

Next Article

Coherus offloads Humira biosimilar Yusimry for $40m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator

STAT+: Saudi VC loops Novo Nordisk, other biotech VCs i...

Nov 29, 2023

Biotechs heed political headwinds for drug pricing negotiations and partnerships

Biotechs heed political headwinds for drug pricing nego...

Feb 28, 2024

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

Mabwell’s 9MW2821 gains FDA fast track status for breas...

Jul 16, 2024